[en] [en] OBJECTIVE: Decreased amyloid beta (Aβ) 42 together with increased tau and phospho-tau in cerebrospinal fluid (CSF) is indicative of Alzheimer's disease (AD). However, the molecular pathophysiology underlying the slowly progressive cognitive decline observed in AD is not fully understood and it is not known what other CSF biomarkers may be altered in early disease stages.
METHODS: We utilized an antibody-based suspension bead array to analyze levels of 216 proteins in CSF from AD patients, patients with mild cognitive impairment (MCI), and controls from two independent cohorts collected within the AETIONOMY consortium. Two additional cohorts from Sweden were used for biological verification.
RESULTS: Six proteins, amphiphysin (AMPH), aquaporin 4 (AQP4), cAMP-regulated phosphoprotein 21 (ARPP21), growth-associated protein 43 (GAP43), neurofilament medium polypeptide (NEFM), and synuclein beta (SNCB) were found at increased levels in CSF from AD patients compared with controls. Next, we used CSF levels of Aβ42 and tau for the stratification of the MCI patients and observed increased levels of AMPH, AQP4, ARPP21, GAP43, and SNCB in the MCI subgroups with abnormal tau levels compared with controls. Further characterization revealed strong to moderate correlations between these five proteins and tau concentrations.
INTERPRETATION: In conclusion, we report six extensively replicated candidate biomarkers with the potential to reflect disease development. Continued evaluation of these proteins will determine to what extent they can aid in the discrimination of MCI patients with and without an underlying AD etiology, and if they have the potential to contribute to a better understanding of the AD continuum.
Disciplines :
Neurologie
Auteur, co-auteur :
Bergström, Sofia ; Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
Remnestål, Julia ; Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
Yousef, Jamil ; Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
Olofsson, Jennie ; Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
Markaki, Ioanna ; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
Carvalho, Stephanie; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Assistance-Publique Hôpitaux de Paris, INSERM, CNRS, Hôpital Pitié-Salpêtrière, Department of Neurology, Centre d'Investigation Clinique Neurosciences, Paris, France
Corvol, Jean-Christophe ; Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, Assistance-Publique Hôpitaux de Paris, INSERM, CNRS, Hôpital Pitié-Salpêtrière, Department of Neurology, Centre d'Investigation Clinique Neurosciences, Paris, France
Kultima, Kim ; Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden
Kilander, Lena; Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, Uppsala, Sweden
Löwenmark, Malin; Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, Uppsala, Sweden
Ingelsson, Martin ; Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, Uppsala, Sweden
Blennow, Kaj ; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg ; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
Zetterberg, Henrik ; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg ; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden ; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK ; UK Dementia Research Institute at UCL, London, UK
Nellgård, Bengt ; Anesthesiology and Intensive Care Medicine, Sahlgrenska University Hospital, Mölndal, Sweden ; Department of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg
Brosseron, Frederic ; Universitätsklinikum Bonn, Germany ; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
Bosch, Beatriz ; Alzheimer's and other cognitive disorders Unit. Service of Neurology, Hospital Clínic de Barcelona, Institut d'Investigació Biomèdica August Pi i Sunyer, University of Barcelona, Barcelona, Spain
Sanchez-Valle, Raquel ; Alzheimer's and other cognitive disorders Unit. Service of Neurology, Hospital Clínic de Barcelona, Institut d'Investigació Biomèdica August Pi i Sunyer, University of Barcelona, Barcelona, Spain
Månberg, Anna ; Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
Svenningsson, Per ; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
Nilsson, Peter ; Division of Affinity Proteomics, Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking (AETIONOMY, grant n. 115568) including in‐kind contributions from the EFPIA members involved. The work was also funded by KTH Center for Applied Precision Medicine (KCAP), the Erling‐Persson Family Foundation, Demensfonden, and Stockholm Brain Institute. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018‐02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG‐720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809‐2016862), AD Strategic Fund and the Alzheimer's Association (#ADSF‐21‐831376‐C, #ADSF‐21‐831381‐C and #ADSF‐21‐831377‐C), the Olav Thon Foundation, the Erling‐Persson Family Foundation, Hjärnfonden, Sweden (#FO2019‐0228), the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska‐Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017‐00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB‐201809‐2016615), the Swedish Alzheimer Foundation (#AF‐742881), Hjärnfonden, Sweden (#FO2017‐0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF‐agreement (#ALFGBG‐715986), and European Union Joint Program for Neurodegenerative Disorders (JPND2019‐466‐236). KK is supported by The Gun and Bertil Stohne’s foundation, Geriatriska fonden, and Stiftelsen för Gamla Tjänarinnor.KB has served as a consultant or at advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis, and Roche Diagnostics, and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen, and is a co‐founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). J.C.C. has served in advisory boards for Air Liquide, Biogen, Denali, Ever Pharma, Idorsia, Prevail Therapeutic, Theranexus, UCB; and received grants from Sanofi and the Michael J Fox Foundation. The other authors declare that they have no competing interest.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.
Blennow K, Zetterberg H. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. Prog Mol Biol Transl Sci 2019;168:3–23.
Blennow K, Hampel H, Weiner M, et␣al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131–144.
Dubois B, Feldman HH, Jacova C, et␣al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014;13:614–629.
Dubois B, Feldman HH, Jacova C, et␣al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734–746.
Whelan CD, Mattsson N, Nagle MW, et␣al. Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease. Acta Neuropathol Commun 2019;7:169.
Simrén J, Ashton NJ, Blennow K, et␣al. An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. Curr Opin Neurobiol 2020;61:29–39.
Hansson O, Zetterberg H, Buchhave P, et␣al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228–234.
Begcevic I, Brinc D, Brown M, et␣al. Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: a targeted mass spectrometry approach. J Proteomics 2018;182:12–20.
Begcevic I, Tsolaki M, Brinc D, et␣al. Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer's disease progression. F1000Res. 2018;7:1012.
Khoonsari PE, Shevchenko G, Herman S, et␣al. Improved differential diagnosis of Alzheimer's disease by integrating ELISA and mass spectrometry-based cerebrospinal fluid biomarkers. J Alzheimers Dis 2019;67:639–651.
Haggmark A, Bystrom S, Ayoglu B, et␣al. Antibody-based profiling of cerebrospinal fluid within multiple sclerosis. Proteomics 2013;13:2256–2267.
Pin E, Sjoberg R, Andersson E, et␣al. Array-based profiling of proteins and autoantibody repertoires in CSF. Method Molecular Biol 2019;2044:303–318.
Haggmark A, Schwenk JM, Nilsson P. Neuroproteomic profiling of human body fluids. Proteomics Clin Appl 2016;10:485–502.
Sjostedt E, Fagerberg L, Hallstrom BM, et␣al. Defining the human brain proteome using transcriptomics and antibody-based profiling with a focus on the cerebral cortex. PLoS One 2015;10:e0130028.
Schwenk JM, Gry M, Rimini R, et␣al. Antibody suspension bead arrays within serum proteomics. J Proteome Res 2008;7:3168–3179.
Schwenk JM, Igel U, Neiman M, et␣al. Toward next generation plasma profiling via heat-induced epitope retrieval and array-based assays. Mol Cell Proteomics 2010;9:2497–2507.
Remnestål J, Just D, Mitsios N, et␣al. CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease. Proteomics Clin Appl 2016;10:1242–1253.
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. 2020.
Wickham H, Averick M, Bryan J, et␣al. Welcome to the {tidyverse}. J Open Source Software 2019;4:1686.
Ripley WNVBD. Modern Applied Statistics with S. New York: Springer, 2002(Fourth).
Hong MG, Lee W, Nilsson P, et␣al. Multidimensional normalization to minimize plate effects of suspension bead array data. J Proteome Res 2016;15:3473–3480.
Uhlen M, Fagerberg L, Hallstrom BM, et␣al. Proteomics. Tissue-based map of the human proteome. Science 2015;347:1260419.
Sjöstedt E, Zhong W, Fagerberg L, et␣al. An atlas of the protein-coding genes in the human, pig, and mouse brain. Science 2020;367:eaay5947.
Blennow K, Bogdanovic N, Alafuzoff I, et␣al. Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Trans. 1996;103:603–618.
Portelius E, Olsson B, Höglund K, et␣al. Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathol 2018;136:363–376.
Brinkmalm A, Brinkmalm G, Honer WG, et␣al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Mol Neurodegener 2014;9:53.
Sandelius A, Portelius E, Kallen A, et␣al. Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. Alzheimers Dement 2019;15:55–64.
Oeckl P, Halbgebauer S, Anderl-Straub S, et␣al. Targeted mass spectrometry suggests beta-synuclein as synaptic blood marker in Alzheimer's disease. J Proteome Res 2020;19:1310–1318.
Denny JB. Molecular mechanisms, biological actions, and neuropharmacology of the growth-associated protein GAP-43. Curr Neuropharmacol 2006;4:293–304.
Oeckl P, Metzger F, Nagl M, et␣al. Alpha-, beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer's and Creutzfeldt-Jakob disease but no alteration in synucleinopathies. Mol Cell Proteomics 2016;15:3126–3138.
Hall S, Öhrfelt A, Constantinescu R, et␣al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445–1452.
Takei K, Slepnev VI, Haucke V, et␣al. Functional partnership between amphiphysin and dynamin in clathrin-mediated endocytosis. Nat Cell Biol 1999;1:33–39.
Wang HF, Wan Y, Hao XK, et␣al. Bridging integrator 1 (BIN1) genotypes mediate Alzheimer's disease risk by altering neuronal degeneration. J Alzheimer's Dis 2016;52:179–190.
Wu Y, Matsui H, Tomizawa K. Amphiphysin I and regulation of synaptic vesicle endocytosis. Acta Med Okayama 2009;63:305–323.
Mader S, Brimberg L. Aquaporin-4 water channel in the brain and its implication for health and disease. Cells 2019;8.
Mawuenyega KG, Sigurdson W, Ovod V, et␣al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010;330:1774.
Zeppenfeld DM, Simon M, Haswell JD, et␣al. Association of perivascular localization of aquaporin-4 with cognition and Alzheimer disease in aging brains. JAMA Neurol. 2017;74:91–99.
Hubbard JA, Szu JI, Binder DK. The role of aquaporin-4 in synaptic plasticity, memory and disease. Brain Res Bull 2018;136:118–129.
Arighi A, Di Cristofori A, Fenoglio C, et␣al. Cerebrospinal fluid level of aquaporin4: a new window on glymphatic system involvement in neurodegenerative disease? J Alzheimer's Dis 2019;69:663–669.
Hoffman PN, Cleveland DW, Griffin JW, et␣al. Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci USA 1987;84:3472–3476.
Khalil M, Teunissen CE, Otto M, et␣al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577–589.
Bridel C, van Wieringen WN, Zetterberg H, et␣al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology. A systematic review and meta-analysis. JAMA Neurol 2019.
Gisslén M, Price RW, Andreasson U, et␣al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135–140.
van der Ende EL, Meeter LH, Poos JM, et␣al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol 2019;18:1103–1111.
Sanchez-Valle R, Heslegrave A, Foiani MS, et␣al. Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease. Alzheimer's Res Ther 2018;10:113.
Disanto G, Barro C, Benkert P, et␣al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017;81:857–870.
Weston PSJ, Poole T, Ryan NS, et␣al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology 2017;89:2167–2175.
Lewczuk P, Ermann N, Andreasson U, et␣al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. Alzheimer's Res Ther 2018;10:71.
Remnestål J, Öijerstedt L, Ullgren A, et␣al. Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers. Transl Neurodegener 2020;9:27.
Haggmark A, Mikus M, Mohsenchian A, et␣al. Plasma profiling reveals three proteins associated to amyotrophic lateral sclerosis. Ann Clin Trans Neurol 2014;1:544–553.
Rakhilin SV, Olson PA, Nishi A, et␣al. A network of control mediated by regulator of calcium/calmodulin-dependent signaling. Science 2004;306:698–701.
Benowitz LI, Routtenberg A. GAP-43: an intrinsic determinant of neuronal development and plasticity. Trends Neurosci 1997;20(2):84–91.
Berggård T, Arrigoni G, Olsson O, et␣al. 140 mouse brain proteins identified by Ca2+-calmodulin affinity chromatography and tandem mass spectrometry. J Proteome Res 2006;5:669–687.
Zetterberg H. Review: Tau in biofluids - relation to pathology, imaging and clinical features. Neuropathol Appl Neurobiol 2017;43:194–199.
Blom ES, Giedraitis V, Zetterberg H, et␣al. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord 2009;27:458–464.
Wallin AK, Blennow K, Zetterberg H, et␣al. CSF biomarkers predict a more malignant outcome in Alzheimer's disease. Neurology 2010;74:1531–1537.
Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med 2018;284:643–663.
Wesenhagen KEJ, Teunissen CE, Visser PJ, et␣al. Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: a literature review. Crit Rev Clin Lab Sci 2019;1–13.
Dayon L, Núñez Galindo A, Wojcik J, et␣al. Alzheimer disease pathology and the cerebrospinal fluid proteome. Alzheimer's Res Ther 2018;10:66.
Andersson A, Remnestal J, Nellgard B, et␣al. Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease. Clinica Chimica Acta 2019;494:79–93.
